While systemic administration of IL-15:IL-15Ra complexes did drive splenomegaly, due to peripheral expansion of peripheral NK and CD8 T cell populations73,74, our data indicates that treatment promoted both a tissue-resident phenotype and superior effector function for NK cells specifically within the tumor. This evidence concerns the gene IL15 and neoplasm.